EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE
Pre-Launchefavirenz; lamivudine; tenofovir disoproxil fumarate
NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
1/8 — Limited
EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE (efavirenz; lamivudine; tenofovir disoproxil fumarate) by Hetero is fixed-dose combination of antiviral drugs efv, 3tc, and tdf with antiviral activity against hiv-1 [see ].
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
This is a fixed-dose combination tablet containing efavirenz, lamivudine, and tenofovir disoproxil fumarate—three antiviral agents with proven activity against HIV-1. The combination leverages complementary mechanisms to suppress viral replication and is administered orally once daily. It is designed for treatment-naive and treatment-experienced HIV patients seeking simplified, single-tablet regimen therapy.
PRE_LAUNCH
As a pre-launch product from Hetero, this combination represents a greenfield opportunity for commercial teams to build market presence in the competitive HIV treatment landscape.
Mechanism of Action
fixed-dose combination of antiviral drugs EFV, 3TC, and TDF with antiviral activity against HIV-1 [see ].
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This pre-launch HIV combination offers career opportunity in a mature therapeutic area with significant global demand, particularly in emerging markets where Hetero has manufacturing and distribution strength. Success depends on pricing competitiveness, payer negotiations, and geographic market penetration rather than clinical differentiation.
Brand ManagerMarket Access Manager
Worked on EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE at Hetero? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.